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Introduction
Type 2 diabetes (T2D) is a well-established risk factor for 
cardiovascular (CV) and cerebrovascular disease [1-3]. 
However, the extent to which its impact on vascular risk 
varies according to levels of conventional risk factors 
was, until recently, unknown. A meta-analysis of 102 
prospective studies (n = 698,782) from the Emerging Risk 
Factors Collaboration demonstrated that T2D confers 
approximately a twofold excess risk for a wide range of 
vascular diseases, including coronary heart disease 
(CHD; hazard ratio (HR) = 2.00, 95% conﬁ dence interval 
(CI)  =  1.83 to 2.19), ischaemic stroke (HR  =  2.27, 95% 
CI = 1.95 to 2.65), haemorrhagic stroke (HR = 1.56, 95% 
CI = 1.19 to 2.05), and other vascular deaths (HR = 1.73, 
95% CI = 1.51 to 1.98) (Figure 1) [2]. T2D was a strong 
predictor for CV risk in all patient subgroups, and was 
more strongly associated with fatal versus nonfatal 
disease. HRs were largely unaﬀ ected by inﬂ ammatory/
renal markers and the lipid proﬁ le (non-high-density 
lipo protein, high-density lipo protein and triglyceride 
levels). Th is study demonstrates that the association 
between T2D and vascular disease cannot fully be 
explained by conventional or emerging CV risk factors 
and suggests that the causal factors by which diabetes 
increases CV disease have yet to be deﬁ ned.
T2D accounts for approximately 10% of all vascular 
deaths in developed countries over the past 10 years [2] 
and is associated with an increased risk of death from a 
range of other conditions, including some cancers, infec-
tious diseases, external causes, intentional self-harm, and 
some degenerative disorders [4]. Data from 97 
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pros pec tive studies (n  =  820,900) suggest that, on 
average, a 50 year old with T2D and no history of vascular 
disease dies approximately 6 years before their counter-
part without T2D [4]. Whereas the risk of death is 
directly associated with levels of fasting plasma glucose 
(FPG) in the diabetic range (>5.6  mmol/l; 100  mg/dl), 
there appears to be only a modest correlation between 
FPG levels in the nondiabetic range (3.9 to 5.6 mmol/l; 70 
to 100  mg/dl) [4]. Similarly, the Emerging Risk Factors 
Colla boration found that assessment of neither FPG con-
centration nor impaired fasting glucose status signi-
ﬁ cantly improved vascular disease prediction in people 
without T2D beyond that obtained from conventional 
risk factors. Moreover, although both early-onset and 
late-onset T2D are associated with an increased risk of 
major CHD events and mortality, only long-duration 
T2D (>10 years) appears to be a CHD risk equivalent [3]. 
Together, these studies suggest that the duration of hyper-
glycaemia might contribute to the association between 
T2D and vascular risk.
Th e impact of hyperglycaemia on T2D-related vascular 
risk was further examined by a meta-analysis of ﬁ ve 
randomised clinical trials (n  =  33,040) comparing the 
eﬀ ects of intensive versus standard glycaemic control in 
people with T2D [1]. Compared with standard glycaemic 
control, intensive control reduced mean glycated haemo-
globin A1c (HbA1c) levels by 0.9%, resulting in a 17% 
reduction in the risk of nonfatal myocardial infarction 
(odds ratio  =  0.83, 95% CI  =  0.75 to 0.93) and a 15% 
reduction in the risk of CHD (odds ratio  =  0.85, 95% 
CI = 0.77 to 0.93) with no signiﬁ cant eﬀ ect on stroke or 
all-cause mortality. However, the reduction in events (2.9 
per 200 T2D patients treated over 5 years) was far more 
modest than that achieved either with lipid-lowering 
therapy (8.2 fewer CV events for each mmol/l reduction 
in low-density lipoprotein-cholesterol) or with anti hyper-
tensive treatment (12.5 fewer events per 4 mmHg reduc-
tion in systolic blood pressure) [1]. Similarly, the Diabetes 
Reduction Assessment with Ramipril and Rosiglitazone 
Medication (DREAM) study (n  =  5,269) showed that, 
although oral hypoglycaemic agents can increase the 
likelihood of regression to normoglycaemia and can 
reduce the incidence of T2D in adults with impaired FPG 
and/or impaired glucose tolerance, they have very little 
eﬀ ect on CV event rates [5].
Overall, these results suggest that T2D and dys gly-
caemia are diﬀ erent entities and that the CV risk 
associated with dysglycaemia is modest.
Some statins are associated with an increased risk 
of new-onset type 2 diabetes
Numerous studies have shown that reducing low-density 
lipoprotein-cholesterol levels using statins signiﬁ cantly 
reduces CV risk in people with and without T2D [6-10]. 
Although statins are generally safe and well tolerated [11], 
conﬂ icting data exist regarding the eﬀ ects of some statins 
on the risk of incident T2D [12-17]. For example, the 
Justiﬁcation for the Use of Statins in Primary Preven tion: 
An Intervention Trial Evaluating Rosuva statin (JUPITER) 
study (n = 17,802) showed a signiﬁ cant 3.0% versus 2.4% 
Figure 1. Type 2 diabetes confers excess risk for a wide range of vascular diseases. *Adjusted for age, smoking, BMI, systolic blood pressure 
and stratifi ed by sex and trial arm (where appropriate). **Includes fatal and nonfatal events.
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increase in incident T2D among healthy adults treated 
with rosuvastatin 20 mg/day versus placebo for 1.9 years 
(P  =  0.01) [12]. Th is was accompanied by a small but 
signiﬁ cant increase in HbA1c levels. In con trast, the West 
of Scotland Coronary Prevention Study (WOSCOPS; 
n  =  5,974) showed that, compared with placebo, prava-
statin was associated with a 30% reduction (P = 0.042) in 
the hazard of developing T2D after 5 years [13].
To investigate this discrepancy, a meta-analysis of 13 
statin trials was performed, including 91,140 patients 
without T2D [15]. In this analysis, statin therapy (atorva-
statin 10  mg, pravastatin 40 mg, simvastatin 40 mg or 
rosuvastatin 20 mg) was associated with a 9% increased 
risk for T2D over 4 years (odds ratio = 1.09, 95% CI = 1.02 
to 1.17), with only a small degree of heterogeneity 
(I2  =  11%) between trials (Figure  2). A further meta-
analysis showed that the potential diabetogenic eﬀ ects of 
statins may be dose related [14]. Compared with 
moderate therapy, intensive therapy (simvastatin 80 mg 
or atorvastatin 80 mg) was associated with a higher 
incidence of T2D (odds ratio  =  1.12), with no hetero-
geneity between trials (I2 = 0%). Similar results were also 
obtained from a post-hoc analysis of the Stroke Preven-
tion by Aggressive Reduction in Cholesterol Levels 
(SPARCL) trial (n  =  3,803) [17]. Incident T2D occurred 
in 8.71% of patients randomised to atorvastatin 80  mg/
day and in 6.06% of patients receiving placebo (adjusted 
HR = 1.37, 95% CI = 1.08 to 1.75; P = 0.011).
Although these results suggest a correlation between 
statin therapy and incident T2D, it should be noted that 
none of the statin trials were designed to look for incident 
T2D and that the meta-analyses used a range of methods 
to detect the condition. Further studies are therefore 
required to fully understand this eﬀ ect.
What does this mean for our patients?
Th e beneﬁ ts of intensive versus standard statin therapy 
on CV outcomes in people with and without T2D have 
been clearly established [6,18-21]. For example, the 
Treat to New targets (TNT) study (n  =  10,001) found 
that the total number of CV events prevented per 5,000 
patients treated with atorvastatin 80  mg versus 
atorvastatin 10  mg for 5  years was 608 (262 prevented 
for the ﬁ rst event, and 166, 92, 55 and 33 prevented for 
the second, third, fourth and ﬁ fth events) [18]; similar 
ﬁ ndings were observed in the subgroup of patients with 
T2D or metabolic syn drome (n  =  5,854). Th ese results 
are further corro borated by a meta-analysis carried out 
by the Cholesterol Treatment Trialist’s Collaboration, in 
which more versus less intensive statin therapy was 
associated with a highly signiﬁ cant 15% (95% CI = 11 to 
18; P  <0.0001) further reduction in major vascular 
events [6]. Importantly, each 1.0  mmol/l decrease in 
low-density lipoprotein-choles terol reduced the annual 
rate of major CV events by 21% in patients both with 
and without T2D [6,21].
Based on these results [6,21], Sattar and colleagues 
found that treating 255 patients with standard-dose statin 
therapy for 4 years would, on average, avoid a composite 
of nine vascular events whilst leading to one case of 
statin-related T2D (9:1 beneﬁt vs. risk ratio) [15]. 
Similarly, Preiss and colleagues found that, compared 
with standard therapy, the number needed to harm per 
year for intensive statin therapy was 498 for incident T2D 
whereas the number needed to treat per year was 155 for 
CV events [14]. In absolute terms, intensive statin therapy 
accounted for 3.0 additional cases of T2D and 6.5 fewer 
ﬁ rst major CV events per 1,000 patient-years.
Together, these studies suggest that the overwhelming 
beneﬁts for intensive-dose statins in reducing CV events 
far outweigh the small absolute risk for developing T2D. 
Authors therefore conclude that statins should still be 
considered as a ﬁ rst-line therapy for dyslipidaemia in the 
majority of patients with CV risk.
Are all statins the same?
Mechanisms explaining the potentially higher incidence 
of T2D with statin therapy have not yet been identiﬁ ed. 
Possible explanations include residual confounding 
factors, such as improved survival with statin treatment 
and an improved lifestyle after CV events. However, 
independent predictors for statin-associated T2D appear 
to include elevated levels of baseline FPG, BMI, blood 
pressure and fasting triglycerides [17]. Moreover, although 
some statins have been associated with increased HbA1c 
levels in patients receiving intensive therapy, other statins 
have demonstrated neutral or favourable eﬀ ects on glucose 
control in patients with and without T2D [16,22-31].
Analysis of data from the PROVE-IT TIMI 22 trial 
showed that, among the 3,382 patients without pre-
existing T2D, HbA1c levels increased by 0.12% in patients 
treated with pravastatin 40  mg and by 0.30% in those 
receiving atorvastatin 80 mg (P <0.0001) [23]. However, 
these results were obtained from a post hoc analysis and 
must be interpreted with caution. Similarly, a comparison 
of glycaemic control between T2D patients receiving 
ator va statin 10  mg, pravastatin 10  mg or pitavastatin 
2  mg/day (n  =  279) showed that glycaemic parameters 
(arbi trary blood glucose levels and HbA1c) only 
increased among atorvastatin-treated patients [24]. Since 
there was no correlation between changes in HbA1c and 
changes in low-density lipoprotein-cholesterol, the 
mecha nism of statin-eﬀ ects on glycaemic control were 
deemed to be unrelated to lipid proﬁ le. Again, these data 
should be treated with caution due to the retrospective, 
single-site nature of the study. However, the results are 
consistent with those from a subanalysis of the CHIBA 
study in which 45 Japanese patients with T2D and 
Ray Cardiovascular Diabetology 2013, 12(Suppl 1):S3 
http://www.cardiab.com/supplements/12/S1/S3
Page 3 of 6
hyper choles terol aemia were randomised to pitavastatin 
2 mg or ator vastatin 10 mg for 12 weeks [25]. Whereas 
atorvastatin was associated with a signiﬁ cant increase in 
serum glyco albumin levels (+0.67 ± 1.31% vs. baseline; 
P  =  0.026) and a slight increase in HbA1c levels 
(P = 0.098), pitavastatin had no obvious eﬀ ect.
In contrast to atorvastatin’s negative eﬀ ects, pita va-
statin appears to have a neutral and possibly beneﬁ cial 
eﬀ ect on glucose regulation. Th e CHIBA study showed 
slight increases in FPG, insulin and the homeostasis 
model assessment ratio with atorvastatin but not pita va-
statin [25]. More recently, the CAPITAIN study showed 
that 6-month treatment with pitavastatin 4  mg did not 
signiﬁ cantly change the mean FPG, homeostasis model 
assessment index, insulin levels, insulin/glucose ratios, or 
HbA1c levels in people with metabolic syndrome [30]. 
Two further studies showed that 12-week treatment with 
pitavastatin 4 mg had no eﬀ ect on FPG levels in patients 
with primary hyperlipidaemia or mixed dyslipidaemia 
and ≥2 additional risk factors for CHD [32], and no eﬀ ect 
on FPG, fasting plasma insulin, HbA1c, HOMA-IR or 
QUICKI in patients with primary hyperlipidaemia or 
mixed dyslipidaemia [33]. Further more, a subanalysis of 
the LIVALO Eﬀ ectiveness and Safety (LIVES) study 
showed a signiﬁ cant (P <0.001) 0.28% decrease in HbA1c 
levels among 308 patients with T2D after 104 weeks of 
pitavastatin treatment [26].
Together these data suggest that, whereas some statins 
have negative eﬀ ects on glucose control, pitavastatin has 
a neutral and possibly beneﬁ cial eﬀ ect. However, much of 
the evidence derives from relatively small, retrospective 
and/or single-centre studies and requires conﬁ rmation in 
more robust trials. One such study – the Japan Preven-
tion Trial of Diabetes by Pitavastatin in Patients with 
Impaired Glucose Tolerance (J-PREDICT) study – is an 
open-label, randomised controlled, parallel-group com-
para tive study designed to evaluate the cumulative inci-
dence of new-onset T2D in ~1,240 patients with 
impaired glucose tolerance following 5-year treatment 
with pitavastatin 1 to 2  mg/day [34]. Th is study will be 
completed in 2015.
In conclusion, conﬂ icting data exist regarding the dose-
dependent diabetogenic eﬀ ects of statins. Whereas some 
statins (for example, atorvastatin, pravastatin, rosuva-
statin and simvastatin) appear to have adverse eﬀ ects on 
glycaemic control, others (for example, pitavastatin) 
appear to have a neutral and possibly favourable eﬀ ect. 
However, more robust studies are required to conﬁ rm 
these results and to fully understand their clinical 
implications. In the meantime, the net CV beneﬁ t favours 
the use of statin therapy in patients with dyslipidaemia, 
irrespective of T2D risk.
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Figure 2. Statin therapy is associated with an increased risk of type 2 diabetes [15]. Events per 1,000 patient-years; weights are from random-
eff ects analysis. CI, confi dence interval; OR, odds ratio.
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